More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts

 
• By Bridget Silverman

Only one-third of novel agents with 2025 goal dates come from the traditional oncology, hematology and neuroscience strongholds. Immunodermatology also is cooling, while cardiovascular drugs return to the front burner.

The US FDA is looking at a shifting landscape of potential novel agents in the class of 2025. (Shutterstock)

More from Pink Sheet Perspectives

More from Geography